Fragile X Syndrome (FXS) Treatment Market, By Type (Diagnosis, Treatment), By Related Disorders (Fragile X Tremor-Ataxia Syndrome, FMR1-Related Primary Ovarian Insufficiency, Fragile XE Syndrome, Renpenning Syndrome, Others), By End Users (Hospitals, Specialty Clinics Others), By Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI476221 | Publish Date: May 2023 | No. of Pages: 150

Global Fragile X Syndrome FXS Treatment Market Overview

Fragile X Syndrome is a hereditary illness caused by a CGG trinucleotide expansion in the fragile X mental retardation 1 gene locus Xq27.3, known as a complete mutation (more than 200 CGG repetitions). It causes a hyper-methylated area in the gene promoter, which silences the gene and reduces the expression of fragile X mental retardation 1, a protein involved in synaptic plasticity and maturation. It is thought to be the most prevalent genetic cause of mental retardation. At adolescence and beyond, people with FXS have intellectual handicap, autism, hyperactivity, a long face, large or prominent ears, and macroorchidism. Language delay, sensory hyper arousal, and anxiety are common in young children with FXS. Intellectual disability, behavioral and academic difficulties, and a variety of physical traits are all symptoms of FXS.  Though both genders are afflicted by FXS, males are affected more frequently and with greater severity than females. Because there are normally no life-threatening health complications linked with FXS, people's life expectancy is unaffected. In comparison to one-third of women, the majority of men with fragile X syndrome have mild to severe intellectual disabilities. Anxiety and hyperactive behavior, such as fidgeting or impulsive conduct, are common in children with fragile X syndrome. These children may also have trouble maintaining their attention and concentrating on specific tasks. Around one-third of people with fragile X syndrome show autism spectrum disorder characteristics that interfere with communication and social interaction. Fragile X syndrome affects about 15% of men and 5% of women, and it can cause seizures. The Global Fragile X Syndrome Market accounted for US$ 55.89 billion in 2020 and is estimated to be US$ 335.15 billion by 2030 and is anticipated to register a CAGR of 19.8%.

Global Fragile X Syndrome FXS Treatment Market Dynamics

Prevalence of fragile X syndrome is increasing

The prevalence of fragile X syndrome is increasing due to a lack of public understanding about genetic illnesses that cause DNA abnormalities. Fragile X syndrome is more common in those who smoke, drink alcohol during pregnancy, or have inherited diseases. The pipeline for the worldwide fragile X syndrome market is expected to grow fast over the forecast period, owing to pharmaceutical and biotechnology companies' increased focus on conducting research programs to find effective therapeutic medicines for the disease's treatment.

Presence of solid pipeline

The presence of a solid pipeline, on the other hand, supports market growth by increasing the emphasis of pharmaceutical and biotechnology companies on performing research projects for the effective treatment of syndrome. Furthermore, increased incidences of genetic mutation syndromes and an increase in hazardous lifestyles (such as smoking, consuming alcohol, and others) among pregnant women are driving market expansion. However, in underdeveloped nations, a lack of awareness of the illness and the high cost of treatment may hamper the global Fragile X Syndrome (FXS) treatment market.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Fragile X Syndrome FXS Treatment Market Segmentation

 

                                                                    

                                                                                                      Source: Prophecy Market Insights

                                        Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.

The Global Fragile X Syndrome Market is segmented based on type, related disorder, end-users, distribution channel and region.

On the basis of Type, the Global Fragile X Syndrome Market is segmented into Diagnosis, Treatment. Based on Related Disorder, the target market is segmented into Fragile X Syndrome, FMR1-Related Primary Ovarian Insufficiency, Fragile XE Syndrome, Renpenning Syndrome, Others. Based on End-User, the target market is segmented into Hospitals, Specialty Clinics Others. Based on Distribution Channel, the target market is segmented into Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others.

Regional Insights:

On region the Global Fragile X Syndrome Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America has the greatest market share in terms of geographical estimation, owing to high healthcare expenditure and research and development. Due to improved healthcare facilities, Europe holds the second greatest market share. Due to increased advancement in technology, growing healthcare expenditure, and rising awareness programmes, Asia-Pacific is predicted to account for the highest market share in the Fragile X Syndrome (FXS) treatment market in the approaching years.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2030

Market representation

Revenue in USD Million & CAGR from 2020 – 2029

Market Segmentation

By Type- Diagnosis, Treatment

By Related Disorder– Fragile X Syndrome, FMR1-Related Primary Ovarian Insufficiency, Fragile XE Syndrome, Renpenning Syndrome, Others

By End-User- Hospitals, Specialty Clinics, Other

By Distribution Channel- Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the Global Fragile X Syndrome Market report based on type, related disorder, end-user, distribution channel and region.

 

Global Fragile X Syndrome Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Global Fragile X Syndrome FXS Treatment Market Key Players

The major players covered in the Fragile X Syndrome (FXS) treatment market are Ovid Therapeutics., BELLUS Health Inc., AMO PHARMA, Neuren Pharmaceuticals, Anavex Life Sciences Corp., Karus Therapeutics. Prominent players operating in the target market are focusing on the strategic partnerships as well as launching of the products in order to gain competitive edge in the target market.

Global Fragile X Syndrome FXS Treatment Market Company Profile

  • Ovid Therapeutics
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • BELLUS Health Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • AMO PHARMA
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Neuren Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Anavex Life Sciences Corp.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Karus Therapeutics
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies

Global Fragile X Syndrome FXS Treatment Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Fragile X Syndrome Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Type
      • Market Snippet, By Related Disorder
      • Market Snippet, By End-User
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global Fragile X Syndrome Market, By Type, 2020 – 2030, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Diagnosis
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Treatment
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
  6. Global Fragile X Syndrome Market, By Related Disorder, 2020 – 2030, (US$ Bn)
    • Overview               
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Fragile X Syndrome
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • FMR1-Related Primary Ovarian Insufficiency
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Fragile XE Syndrome
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Renpenning Syndrome
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
  7. Global Fragile X Syndrome Market, By End-User, 2020 – 2030, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Hospitals
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Specialty Stores
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
  8. Global Fragile X Syndrome Market, By Distribution Channel, 2020 – 2030, (US$ Bn)
    • Overview            
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Direct Tender
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Hospital Pharmacy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Retail Pharmacy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Online Pharmacy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
  9. Global Fragile X Syndrome Market, By Region, 2020 – 2030, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Bn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Related Disorder, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Bn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Related Disorder, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Bn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Related Disorder, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Bn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Related Disorder, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Bn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Related Disorder, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  10. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  11. Company Profiles
  • Ovid Therapeutics
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • BELLUS Health Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • AMO PHARMA
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Neuren Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Anavex Life Sciences Corp.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Karus Therapeutics
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  1. The Last Word
    • Future Impact
    • About Us
    • Contact

FAQs

The Global Fragile X Syndrome Market is segmented based on type, related disorder, end-users, distribution channel, and Region.

Prevalence of fragile X syndrome is increasing which is the major factor driving growth of the global market

North America has the greatest market share in terms of geographical estimation, owing to high healthcare expenditure and research and development.

The major players covered in the Fragile X Syndrome (FXS) treatment market are Ovid Therapeutics., BELLUS Health Inc., AMO PHARMA, Neuren Pharmaceuticals, Anavex Life Sciences Corp., Karus Therapeutics.